Natera, Inc. (NASDAQ:NTRA) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

On March 12, 2026, Natera, Inc. (NASDAQ:NTRA) announced the commercial launch of Zenith, a whole-genome sequencing assay engineered to significantly improve the diagnosis of rare genetic conditions. Zenith, with its genomic analysis, aims to shorten the diagnostic odyssey for the 30 million Americans affected by rare diseases. In its announcement, the company pointed out the huge unmet need in the sector and noted that the cumulative economic burden of rare diseases in the U.S. reached nearly $997 billion in 2019 alone. Using the new clinical tool will provide access to timely and accurate results that could significantly assist in providing definitive answers to families of rare disease patients.

In an unrelated event, Morgan Stanley lowered its price target on Natera, Inc. (NASDAQ:NTRA) from $265 to $250 on March 3, 2026, after updating its model following the fourth-quarter results. The firm kept an Overweight rating on the company’s stock.

Founded in 2004, Natera, Inc. (NASDAQ:NTRA) is a leader in cell-free DNA (cfDNA) testing for oncology, women’s health, and organ health. Its headquarters is in Texas.

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.